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Abstract
Although controversial, recent studies suggest that serous ovarian carcinomas may arise from fallopian tube fim-
bria rather than ovarian surface epithelium. We developed an in vitro model for serous carcinogenesis in which
primary human fallopian tube epithelial cells (FTECs) were exposed to potentially oncogenic molecular alterations
delivered by retroviral vectors. To more closely mirror in vivo conditions, transformation of FTECs was driven by the
positive selection of growth-promoting alterations rather antibiotic selection. Injection of the transformed FTEC
lines in SCID mice resulted in xenografts with histologic and immunohistochemical features indistinguishable from
poorly differentiated serous carcinomas. Transcriptional profiling revealed high similarity among the transformed
and control FTEC lines and patient-derived serous ovarian carcinoma cells and was used to define a malignancy-
related transcriptional signature. Oncogene-treated FTEC lines were serially analyzed using quantitative reverse
transcription–polymerase chain reaction and immunoblot analysis to identify oncogenes whose expression was
subject to positive selection. The combination of p53 and Rb inactivation (mediated by SV40 T antigen), hTERT
expression, and oncogenic C-MYC and HRAS accumulation showed positive selection during transformation.
Knockdown of each of these selected components resulted in significant growth inhibition of the transformed cell
lines that correlated with p27 accumulation. The combination of SV40 T antigen and hTERT expression resulted in
immortalized cells that were nontumorigenic in mice, whereas forced expression of a dominant-negative p53 iso-
form (p53DD) and hTERT resulted in senescence. Thus, our investigation supports the tubal origin of serous car-
cinoma and provides a dynamic model for studying early molecular alterations in serous carcinogenesis.
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Introduction
Epithelial ovarian cancer is the most lethal female reproductive ma-
lignancy, yet our knowledge of its cellular origins and mechanisms of
carcinogenesis remains notably incomplete. The study of early events
in ovarian carcinogenesis is hampered by the fact that more than
80% of ovarian cancers have already metastasized beyond the ovary
at the time of diagnosis. During the last decade, observations in women
undergoing risk-reducing (prophylactic) salpingo-oophorectomy due
to hereditary breast-ovarian cancer syndrome have led to an increased
understanding of early ovarian cancer. Approximately 5% of women
undergoing risk-reducing surgery are diagnosed with an occult ovarian
cancer (high-grade serous carcinoma in most cases) [1,2]. Most of these
early cancers are either located in the fimbrial potion of the fallopian
tube or have a coexisting carcinoma in situ component in the fimbria
[3–5]. Work by Crum, Piek, and others has shown that careful sec-
tioning of fallopian tubes from risk-reducing salpingo-oophorectomy
specimens frequently reveals areas of marked cytologic atypia and
disorganized growth within the fimbria. These areas have been called
carcinoma in situ or tubal dysplasia [6,7] and are characterized by pos-
itive p53 immunostaining (which correlates with mutations in the
TP53 gene), abnormal proliferation, and DNA damage [8]. Further-
more, approximately a third of morphologically normal fimbria from
women without hereditary ovarian cancer risk exhibit areas of p53
staining without atypia or abnormal proliferation, referred to as p53
signature or foci [8–10]. Collectively, these observations have led to
the hypothesis that most serous carcinomas that are clinically classified
as ovarian or peritoneal may in fact arise from the fallopian tube’s epi-
thelium. However, given that much of this research has been per-
formed on archival paraffin-embedded tissues, direct testing of this
hypothesis has proven difficult. Here, we present direct evidence that,
by acquiring oncogene activation and tumor suppressor dysfunction,
human fallopian tube epithelial cells (FTECs) can transform into a
high-grade carcinoma that closely resembles serous carcinoma. Fur-
thermore, we describe a clinically relevant experimental model that is
well suited for investigating the earliest stages of carcinogenesis that
are currently undetectable or inaccessible in vivo.
Materials and Methods
Primary Cell Cultures of Fallopian Tube Fimbria,
Serous Ovarian Carcinomas, and Tumor Xenografts
After institutional review board approval, deidentified fallopian
tube fimbrial specimens were obtained from salpingo-oophorectomy
specimens performed for benign gynecologic indications by the Uni-
versity of Virginia’s tissue procurement facility. Specimens from
procedures performed for infectious, inflammatory, or endometriosis-
related procedures were excluded. Fimbria were incubated in RPMI
supplemented with antibiotics and antimycotics for 3 hours at 4°C,
rinsed in sterile phosphate-buffered saline (PBS), and incubated in
dispase I solution (0.26 mg/ml) overnight at 4°C. FTECs were har-
vested from the dispase solution by centrifugation, rinsed with PBS,
and plated on collagen I–coated plates (Fisher, Suwanee, GA) in
FTEC medium, which consists of Medium 171 (Invitrogen, Carlsbad,
CA) supplemented with commercially mixture of cytokines and growth
factors (MEGM singlequots; Lonza, Allendale, NJ), and left undis-
turbed for 3 to 4 days at 37°C in a humidified 5%CO2 incubator. Cells
are propagated on collagen plates for two to three passages and checked
for epithelial cell composition using cytokeratin immunofluorescence
(see next paragraphs). Before retroviral infection, FTECs are plated onto
polystyrene uncoated plates (Corning, Corning, NY) in Dulbecco mod-
ified Eagle medium (DMEM) + 10% fetal bovine serum (FBS).
Primary human high-grade ovarian serous carcinoma cell lines
were established using a similar protocol. After incubation in RPMI
supplemented with antibiotics and antimycotics and PBS wash,
tumor explants were minced into 1- to 3-mm pieces before dispase
treatment as noted above. Tumor cells were then collected by gently
aspirating the dispase digest solution away from any remaining tumor
nodules into a fresh tube followed by centrifugation. Cell pellets were
then rinsed with PBS and plated in OVT medium, which consists of
FTEC medium (see above) + 10% FBS on plastic dishes and left un-
disturbed for 3 to 4 days at 37°C in a humidified 5% CO2 incubator.
Primary serous ovarian cancer cells are propagated on uncoated poly-
styrene plates and are checked for epithelial composition by cyto-
keratin immunofluorescence. After three to four passages, these cells
are transitioned to DMEM + 10% FBS for in vitro experiments.
Limiting Dilution Cloning
Clones were isolated from FTEC74-OC and FTEC76-OC trans-
formed cell lines by plating the cells at limiting dilution in 96-well
plates. Plates were monitored every other day for the presence of sin-
gle colonies, which were expanded.
Preparation of Retroviral Cocktails
HEK293T human embryonic kidney cell lines were obtained
from the American Type Culture Collection (ATCC, Manassas,
VA) where cell identity is verified routinely using short tandem re-
peat analysis, and they are routinely tested for Mycoplasma infections.
Retroviral vectors, except for the short hairpin constructs, were ob-
tained from Addgene (http://www.addgene.org/pgvec1; presented in
Table W1). The short hairpins targeting BRCA1 and luciferase (con-
trol) were designed using a Web-based algorithm (http://katahdin.cshl.
org/siRNA/RNAi.cgi?type=shRNA) according to previously outlined
methods [11] and cloned into pMMP-DEST, a retroviral vector that
has been modified to have a Gateway (Invitrogen) cassette in the
multicloning site. The final retroviral constructs were confirmed using
DNA sequencing. Recombinant retroviral particles were produced by
transient transfection of HEK293T cells (ATCC) along with packag-
ing plasmids (pCMV-dR8.91 and pMD2G-VSVG). The medium
containing recombinant retrovirus was harvested 36 to 40 hours after
transfection. Cellular debris was removed by centrifugation and filtra-
tion through a 0.45-μm filter (Millipore, Billerica, MA). Oncogenic
and control viral cocktails were formed by mixing equal volumes of
the corresponding components (Table W1), aliquoting the mixture,
and storing single-use vials at −80°C.
Modeling of FTEC Transformation
Before transduction with OC and CC, the efficiency of a single-
FTEC transduction was determined to be relatively constant at
approximately 15% using viral particles generated by pBABE-GFP
vector. Given this infection efficiency and using the binomial dis-
tribution as an approximation, we calculated that 14 retroviral infec-
tions would be required to ensure that 90% of the cells were infected
at least once. This would also result in 64% being infected at least
twice, 35% three times, 15% four times, 5% five times, 1% six
times, 0.2% seven times, and 0.03% eight times. Over time, positive
selection due to growth advantage leads to predominance of the cells
harboring transforming combinations of retrovirally delivered trans-
genes. FTECs were plated in six-well plates in DMEM + 10% FBS.
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For transduction, the normal medium was removed, and FTECs
were treated with 1 ml/well of either the oncogenic or the control
viral cocktail per well for 14 to 16 hours in the presence of polybrene
(4 μg/ml). Cells are washed with PBS, incubated in normal media,
and allowed to recover for 32 to 34 hours before the next infection.
Clonogenic Assays
For focus formation assays, cell lines were plated at a density of
1000 cells/well in six-well dishes and allowed to grow in DMEM
supplemented with 10% FBS for 7 to 10 days. Resulting colonies were
fixed and stained using a mixture of 20% formaldehyde, 80% meth-
anol, and 0.25% crystal violet, and visible colonies were counted. Soft
agar colony formation assay was performed by plating a single-cell agar
(0.35%) suspension of 5000 cells per well in DMEM + 10% FBS on
top of a 1.5% agar-DMEM overlay in a six-well dish. At 14 to 20 days
after plating, colonies were stained with 0.005% crystal violet, and
the number of colonies was noted.
Xenograft Experiments
Animal experiments were performed at the University of Virginia’s
Molecular Assessment and Preclinical Studies core facility with the
approval of the Institutional Animal Care and Use Committee. Four-
to five-week-old Fox Chase SCID mice (strain code 250; Charles
River, Wilmington, MA) were housed in pathogen-free laboratory
animal housing and allowed to acclimate. Mice were injected intra-
peritoneally with 2 × 107 FTECs or SKOV3 (ATCC, positive con-
trol) cells without Matrigel and observed at least twice a week for
tumor formation. Animals were killed once they developed palpable
evidence of tumor or at 3 months after injection.
Immunoblot Analysis and Immunofluorescence
Protein was extracted in RIPA or SDS loading buffer. Protein
concentration was assayed using a BCA protein assay kit (Pierce,
Rockford, IL). About 50 to 100 μg of protein per sample was re-
solved using Tris-glycine gels (Invitrogen) and transferred onto a
nitrocellulose membrane (Amersham, Piscataway, NJ). Immunoblot
analysis was performed in the usual fashion using the following pri-
mary antibodies: anti-p53, C-MYC, GAPDH, BRCA1, and p27 (Cell
Signaling, Danvers, MA); SV40 T Ag, α-tubulin, and p21 (Santa
Cruz Biotechnology, Santa Cruz, CA); β-actin (Sigma, St Louis,
MO); HRAS (Epitomics, Burlingame, CA); and hTERT (Rockland,
Gilbertsville, PA). After primary antibody incubation, membranes were
washed and incubated in a horseradish peroxidase–conjugated cor-
responding secondary antibody for 1 hour. After washes, protein bands
were detected using enhanced chemiluminescence (GE Healthcare,
Piscataway, NJ). For immunofluorescence, cells were plated on cover-
slips in six-well plates overnight, fixed in 4% paraformaldehyde in PBS
for 10 minutes, and rinsed with several washes of PBS. Coverslips were
incubated in blocking solution (PBS with 0.3% Triton X-100 and 5%
normal serum) for 1 hour after which the primary antibody, anti–
pan cytokeratin (Cell Signaling; 1:200) was added for 1 hour at room
temperature. After washes, coverslips were incubated in a fluorescein
isothiocyanate–labeled donkey anti-rabbit secondary antibody (Jackson,
West Grove, PA), washed, and mounted on slides using mounting
medium with 4′,6-diamidino-2-phenylindole (Vector, Burlingame,
CA), sealed with nail polish, and viewed immediately. Slides were exam-
ined using a fluorescent microscope equipped with an Orca II CCD
camera (Hamamatsu, Bridgewater, NJ), and images were acquired using
Zeiss software (Dublin, CA).
Immunohistochemistry
Xenograft tissues were harvested at necropsy and fixed in 10%
neutral formalin overnight and then transferred to 70% ethanol for
24 to 48 hours. Histologic staining and immunohistochemistry were
performed by the pathology core facility and were interpreted by a
gynecologic pathologist (M.H.S.). Briefly, after paraffin embedding,
5-μm sections were processed for antigen retrieval by microwave
treatment in citrate buffer. The primary antibodies used and cor-
responding dilutions are presented in Table W2.
Short Interfering RNA Treatment and MTT Assays
siRNA transfections were carried out using RNAimax transfection
reagent (Invitrogen) per the manufacturer’s protocol. Cells were
transfected twice: 24 and 48 hours after plating to achieve maxi-
mal knockdown. Oligonucleotides were obtained from Dharmacon
(Lafayette, CO), and sequences are provided on request. Cell growth
was evaluated 72 hours after the second siRNA transfection using an
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]
cell growth assay kit (Promega, Madison, WI) according to the manu-
facturer’s instructions.
RNA Extraction and Reverse Transcription–Polymerase
Chain Reaction
Total RNA was purified from cultured cells using the RNeasy
kit (Qiagen, Santa Clarita, CA) including a DNAse treatment step
and quantified with NanoDrop (Thermo Scientific, Portsmouth,
NH). Reverse transcription was performed using Transcriptor First
Strand Synthesis Kit (Roche, Branchburg, NJ). Quantitative reverse
transcription–polymerase chain reaction (RT-PCR) was performed
using SYBR Green Mix (Abgene, Rockford, IL) with 61°C annealing
temperature on an Applied Biosystems StepOnePlus (Foster City, CA).
Internal control glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was detected using Applied Biosystems GAPDH assay.
Microarray Analysis
Five micrograms of total RNA was used to construct biotinylated
complementary RNA labeled and hybridized to an Affymetrix micro-
array chip HG-U133Plus2.0 (Affymetrix, Santa Clara, CA) accord-
ing to the manufacturer’s instructions. The raw data were normalized
using the GeneChip–Robust Multiarray Averaging (GC-RMA) algo-
rithm, and analyses were performed using BRB-ArrayTools developed
by Dr Richard Simon and the BRB-ArrayTools Development Team.
Results
Use of a Positive Selection Screen to Determine the Molecular
Pathways Involved in FTEC Growth and Transformation
We designed our screen based on the current knowledge of mo-
lecular alterations in high-grade serous ovarian cancers (reviewed by
Bowtell [12] and Kobel et al. [13]), as well as previous research by
Kendall et al. [14] on the requirements for transformation of human
cells. Table 1 summarizes the molecular pathways targeted along
with the corresponding rationale, and the overall approach is de-
picted in Figure 1. To ensure that our in vitro approach was relevant
to in vivo mechanisms of carcinogenesis, we devised a growth-directed
selection approach as opposed to forced (antibiotic) selection. We
constructed a cocktail of retroviral vectors to transduce FTEC with
potentially oncogenic molecular alterations (Table 1), henceforth re-
ferred to as the oncogenic cocktail (OC). As a control for nonspecific
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genetic alterations due to retroviral integration, a control cocktail (CC)
was constructed from empty, GFP-expressing, and luciferase-targeting
short hairpin RNA retroviral vectors. Two independent primary FTEC
lines were transduced in parallel with the OC and CC, and their growth
and molecular phenotype were monitored over time. The rationale
for the use of an oncogenic cocktail followed by positive selection
screen is as follows. Single or few oncogene integration events are
unable to impart growth advantage or transformation due to bar-
riers present in normal human cells, namely telomere erosion and
oncogene-induced senescence [15]. In our model, disruption of these
barriers and the resulting transformation would require multiple viral
transduction events in the same cell. This occurs only in a small frac-
tion of the primary cells (please also see the Materials and Methods
section for additional details). Over time, positive selection due to
growth advantage leads to predominance of cells harboring the most
advantageous combinations of retrovirally delivered transgenes. Con-
versely, cells lacking alterations required for growth and bypassing
senescence and other barriers to transformation are subject to neg-
ative selection and extinction.
Growth and Transformation of the OC Transduced FTECs
After allowing a 1-month period of recovery after the retroviral
infections, growth of the two CC and OC transduced FTEC lines
(FTEC74 and FTEC76) was examined using MTT assays (Fig-
ure 2A). Both FTEC-OC lines exhibited a small but statistically sig-
nificant 12% and 17% greater cell numbers at 72 hours compared
with the CC-treated counterparts. After three additional months in
culture, the differential proliferation became much more apparent
with the FTEC74-OC and FTEC76-OC cells exhibiting approxi-
mately three times the number of cells in a 72-hour MTT assay
(Figure 2A). Given this observation, we performed focus formation
assays to look for in vitro evidence of transformation of the OC
treated cells. Both FTEC74-OC and FTEC76-OC cell lines readily
grew and formed foci. In contrast, the FTEC-CC counterparts ex-
hibited little growth and morphologically seemed to be undergoing
senescence (Figure 2B). Soft agar colony formation assays were also
performed and produced 5 to 15 colonies per well in the OC-treated
lines, whereas no colony formation was detected in the FTEC74-CC
and FTEC76-CC cell lines (data not shown).
We next investigated the ability of two FTEC-OC cell lines to
establish xenografts in SCID mice. By this time, both control cocktail-
treated FTEC lines had undergone growth arrest secondary to senes-
cence and, therefore, could not be tested in xenograft studies. Animals
were injected intraperitoneally with 2 × 107 FTEC74-OC, FTEC76-
OC cells, or SKOV3 cells used as a positive control and monitored
Table 1. Targeted Molecular Alterations in Modeling Serous Carcinogenesis.
Pathway Rationale Vector(s) Reference(s)
TP53 TP53 mutations or dysfunctions are nearly ubiquitous in high-grade
serous cancers and also seen tubal carcinoma in situ.
pBABE-p53DD [6,39,40]
pBABE-SV40 LT
BRCA1 BRCA1 mutations result in 45% lifetime risk of ovarian cancer.
Epigenetic silencing, somatic mutations, and other BRCA1
dysfunctions have been reported in a significant portion of
sporadic ovarian cancers.
PMMPmir-BRCA1sh-308 [17,41,42]
pMMPmir-BRCA1sh-5490
C-MYC Frequently amplified and overexpressed in serous cancers. Inversely
correlates with prognosis.
PMSCV-MYC-T58A [43,46]
HRAS Whereas Ras mutations are rare in serous ovarian cancers, abnormal
activation of downstream growth-stimulatory pathways is a key
feature of oncogenesis and required for transformation of human cells.
PBABE-HRAS-G12V [39,47]
RB Alterations in the RB-p16-cyclin D1/CDK4-E2F are seen in 50%
of ovarian cancers.
pBABE-CCND1+CDK4−R24C [47,48]
pBABE-SV40 LT
hTERT Telomere maintenance is a key feature of cellular immortalization and
transformation and required for prevention cell cycle arrest secondary
to senescence or DNA damage response.
pBABE-hTERT [49,50]
GFP Used as a negative control pBABE-GFP
Figure 1. A positive selection screen for the identification of trans-
forming molecular alterations in FTEC. Two independent normal
primary human FTEC lines were transduced with the oncogenic
or control cocktail of retroviral particles creating a heterogeneous
cell population harboring various combinations of genetic altera-
tions (depicted as different colored cells). Over time, through nat-
ural selection, cells with the most effective growth-promoting
genetic alterations are expected to predominate and lead to a
transformed phenotype (depicted in orange).
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for evidence of tumorigenesis. Both FTEC-OC lines proved capable
of establishing xenografts that became detectable at 3 to 4 weeks
after injection. The pattern of disease in both FTEC-OC and SKOV3
xenografts was one of peritoneal carcinomatosis including omental
tumor without intraparenchymal organ involvement or lung metastases
(Figure 2C ).
FTEC-OC Xenografts Recapitulate Poorly Differential
Serous Carcinoma
Histologic and immunohistochemical features of the FTEC74-
OC– and FTEC76-OC–derived xenografts were very similar; these
are presented in Figure 3. The xenografts were composed of poorly
differentiated malignant cells with nuclear pleomorphism, prominent
nucleoli, frequent mitotic figures, and areas of necrosis (Figure 3, A
and B), consistent with the histologic features of patient-derived
poorly differentiated serous carcinoma (Figure 3C ). The immunohis-
tochemical phenotype of the xenografts also closely resembled that of
serous ovarian cancers. The xenografts stained positive for WT1,
p53, HE4 (WFDC2), PAX8, and cytokeratin 7 and were negative
for cytokeratin 20 (Figure 3, D-I ).
To investigate the gene expression phenotype of the transformed
FTEC lines, we performed transcriptional profiling using theAffymetrix
Hgu133plus2 arrays on the two sets of FTEC-OC and FTEC-CC lines
as well as three independent primary normal human fallopian tube cell
lines and three primary human ovarian serous carcinoma lines (OVTs).
Using unsupervised analysis, we determined the overall similarities in
gene expression between FTEC, OVT, FTEC-OC, and FTEC-CC
groups (Figure 4A). Overall, the transcriptional profile of the different
cell lines was remarkably similar (with correlation coefficients from
pairwise comparisons ranging from 0.7 to >0.9), suggesting that the
tissue of origin has a greater influence on transcriptional phenotype
than malignant transformation (Figure 4A). Next, we generated a list
of 123 transcripts that were differentially expressed between the primary
normal FTEC and serous cancer cell lines (F test, P < .005). Using
this gene set, hierarchical clustering segregated the FTEC-OC from
FTEC-CC cells quite robustly with a Pearson correlation coefficient
of −0.6 between the two groups (Figure 4B). To define a transformed/
malignant signature, we compared the combined the OVT and trans-
formed FTEC-OC groups to normal FTEC plus FTEC-CC samples
(Figure 4C). One hundred fifty-eight genes were differentially expressed
(F test, P < .005) between these groups (Figures 4C and W1 and
Table W2). In-depth analysis and validation of the differentially ex-
pressed genes are the subject of ongoing investigation. However, it is
notable that there is little overlap between this list and the lists gener-
ated by studies comparing transcriptional profiles of ovarian cancers
to normal ovaries or ovarian surface epithelial cells [16–19].
Positive Selection of Oncogenes over Time
To determine which growth-promoting molecular alterations are se-
lected over time and thus contribute to FTEC transformation, we se-
rially examined the expression OC components in both FTEC-OC
cells. FTEC74-OC and FTEC76-OC cells were sampled every 3 to
4 weeks after retroviral transduction. In addition, cells from the
corresponding xenografts were also examined for the expression of
the oncogenic viral cocktail components. The oncogenic cocktail tran-
scripts were assayed using real-time RT-PCR using primers designed
to be specific to the retrovirally delivered transgenes with the exception
of hTERT and BRCA1 expression where total (endogenous + exoge-
nous) transcript levels were assayed. As depicted in Figure 5, HRAS
G12V, hTERT, and SV40 T antigen transgene expression increased
over time, whereas C-MYC T58A and CCND1 transcript levels
seemed stable over time but were higher in xenografts. In contrast
p53DD, a dominant-negative isoform of p53 [20] that was included
Figure 2. In vitro and in vivo evidence for FTEC transformation. (A)
The oncogenic cocktail–treated FTEC74 and FTEC76 cells exhib-
ited in vitro growth advantage that increased with time in culture
compared with the control cocktail treated cells as evidenced by
72-hour MTT assays. (B) Focus formation assays performed at ap-
proximately 3 months after transduction. (C) Representative exam-
ple of peritoneal carcinomatosis resulting from intraperitoneal
injection of FTEC-OC cells and a normal mouse shown for compar-
ison. Arrows point to tumor encasing the omentum and serosal
surfaces of the bowel. This closely resembles the disease distribu-
tion seen in patients with advanced stage serous ovarian cancers.
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in the oncogenic cocktail, showed a transient increased expression in
only one of the FTEC lines and no expression in the other cell line.
However, this expression was lost over time, consistent with a lack of
continuing selection (Figure 5). A GFP-expressing vector was included
in both the OC and the CC. Its expression was barely detectable early
after viral transduction and was then lost in both FTEC-OC cells. In-
terestingly, the CC-treated FTECs showed a moderate selection for
GFP expression over time, which may have resulted from exposure
to a much higher dose of GFP vector in the CC mix and/or secondary
retroviral integration effects.
To further evaluate oncogene selection, temporal expression of OC
proteins was evaluated using Western blot analysis; this is presented in
Figure 6. Although minor variations between the two OC-treated
FTEC lines were observed, overall, both demonstrated accumulation
of C-MYC, HRAS, hTERT, and SV40 T antigen proteins during
in vitro transformation and in the corresponding xenografts (Fig-
ure 6A). In contrast, GFP levels significantly declined, and cyclin
D1 levels remained constant over time. Interestingly, in this model,
the selection of SV40 T seemed to negate any selection advantage
for the other components of the oncogenic cocktail targeting the
p53 and Rb pathways (i.e., dominant-negative p53 (p53DD), and
CCND1+CDK4−R24C). In correlation with SV40 T antigen selec-
tion, p53 protein also showed increased expression over time but with-
out any detectable p21 expression (Figure 6A). We suspect that the
observed p53 accumulation resulted from SV40 T antigen–induced
interruption of normal p53 function. Normally, p53 induction leads
to a rapid activation of a negative feedback loop involving MDM2,
resulting in rapid degradation of p53 [21]. In contrast, p53 inactiva-
tion (due to somatic mutations in ovarian cancers or SV40 T expres-
sion in our model) results in paradoxical p53 accumulation. We tested
this hypothesis by knocking down SV40 T in FTEC74-OC and
FTEC76-OC cells. Suppression of SV40 T rescued p53 dysfunction
as evidenced by a decrease in the abnormal accumulation of p53 and
increased p21 (Figure 6B).
Previous studies have reported abnormal p27 (Kip1, CDKN1B)
expression in 33% to 72% of epithelial ovarian cancers as well as
in areas of p53 immunostaining in the fallopian tube’s epithelium
that have been suggested as possible precursors to serous carcinoma
[9,22]. We therefore investigated p27 expression in our model sys-
tem. Notably, p27 expression was present at the earliest time point
analyzed in both FTEC-OC cells lines and persisted in their corre-
sponding xenografts (Figure 6A). This suggests that increased p27
levels may be an early response to oncogenic stress, which, in turn,
could lead to further selection of oncogenes that antagonize p27,
such as C-MYC [23].
Finally, given that the OC contained two short hairpin constructs
targeting BRCA1, the observed temporal increase in BRCA1 at the
transcript and protein levels in both FTEC-OC lines was unexpected
(Figures 5 and 6A). This may indicate selection against BRCA1 short
hairpin RNA–transduced cells. However, we also noted that, in
mouse models of SV40 large and small T antigen–induced carcino-
genesis, tumors in several tissue types exhibited a common transcrip-
tional signature that included increased BRCA1 expression compared
with the corresponding normal tissues [24]. This led us to hypothesize
Figure 3. Histologic and immunohistochemical features of FTEC-OC derived xenografts. Representative low (A, ×20) and high (B, ×200)
magnification of hematoxylin and eosin–stained sections of FTEC76-OC–derived xenografts and a poorly differentiated patient serous
ovarian carcinoma (C, ×200). Immunohistochemical characterization of the xenografts using antibodies targeting cytokeratin 7 (D),
cytokeratin 20 (E), HE4 (also known as WFDC2, F), p53 (G), PAX8 (H), and WT1 (I).
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that the temporal increase in BRCA1 expression in FTEC-OC cells
may be related to SV40 T antigen selection. To test this hypothesis,
we depleted SV40 T in FTEC74-OC and FTEC76-OC cells using
siRNA. Knockdown of SV40 T led to the loss of BRCA1 protein
and (Figure 6C) transcript (data not shown). These data, together with
the previously mentioned study by Deeb et al., suggest that BRCA1 is
positively regulated by SV40 T. The mechanisms for this regulation
await further investigation.
Figure 4. Transcriptional profiling of FTEC and primary serous ovarian cancer cells. (A) Unsupervised pairwise Pearson correlation co-
efficients between untreated FTEC, FTEC-OC, FTEC-CC, and primary ovary cancer (OVT) cell lines. (B) The set of 123 transcripts that
differentiate untreated FTEC and OVT cells also segregate FTEC-OC and FTEC-CC cells into anticorrelated clusters. (C) A malignancy-
related gene list was derived by comparing the profiles of OVT and transformed FTEC-OC cells to those of normal FTEC and the FTEC-
CC cells (see Supplementary Data for the identities and expression levels of the 158 transcripts).
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Figure 5. Serial analysis of the components of oncogenic cocktail expression. Quantitative RT-PCR was used to evaluate the expression
of various OC and CC components at successive time points (approximately every 3 weeks) during in vitro culture of FTEC76 cells, as
well as in cell lines established from the FTEC76-OC–derived xenograft (demarcated by an asterisk). Primers used were specific to
specific to the retrovirally transduced transgenes with the exception of hTERT and BRCA1 expression where total transcript levels were
assayed. Similar patterns of expression were observed in the FTEC74 cell line (data not shown).
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Clonal Analysis Reveals Coexpression of Oncogenes
On the basis of our experimental design, we hypothesized that
transformation of FTEC necessitated the transduction of multiple
oncogenic events in the same cell. Whereas the above serial oncogene
expression data were consistent with such a model, they did not pre-
clude the possibility that the transformed cell lines were composed of
discrete subpopulations expressing some but not all of the oncogenes
selected in the parental cell lines. To address this possibility, we used
limiting dilution to obtain five single-cell–derived sublines from each
of the FTEC-OC–transformed parental lines. The expression levels
of SV40 T, C-MYC T58A, and HRAS G12V were assayed in the
parental and clonal cell lines using real-time RT-PCR (Figure W2).
As expected, the clonal cell lines exhibited varying levels of each
oncogene compared with the parental line. More importantly, this
analysis confirmed that each of the 10 clones had become transduced
by all three selected oncogenes. These results further validate our
experimental model by demonstrating that the transformed cells
generated harbor the full complement of oncogenic alterations iden-
tified through serial expression analysis.
Knockdown of the Selected Oncogenes Inhibits the Growth of
Transformed FTEC Lines
To test whether continued expression of OC components was im-
portant for the growth of transformed FTEC-OC cells, we per-
formed siRNA experiments aimed at suppressing the expression of
the OC components that showed positive selection in these cell lines
(Figure 7). Proliferation of both cell lines was significantly decreased
after knockdown of HRAS, C-MYC, hTERT, and SV40 T. Interest-
ingly, there was no additive effect associated with knocking down
both C-MYC and HRAS, suggesting that these oncogenes may have
a cooperative effect on the growth of the transformed FTECs. Next,
we considered if this growth inhibition could be mediated through
cyclin-dependent kinase inhibitors. Our earlier results had shown that,
in our model, SV40 T selection correlates closely with p53 dysfunction
and p21 suppression (Figure 6,A and B).We hypothesized that because
of its known antagonistic relationship with C-MYC, p27 (CDKN1B)
may also be involved. Knockdown of the selected oncogenes using
siRNA resulted in increased p27 expression (Figure 7C), suggesting that
suppression of p27 may be important for the continued growth of the
transformed FTECs.
Fewer Molecular Alterations Are Not Sufficient for the
Transformation of FTEC
The previously mentioned experiments revealed that activation of
MYC, RAS, and hTERT in addition to interference with p53 and
Rb tumor suppressor pathways (through SV40 T expression) was re-
quired for FTEC transformation. To investigate the possibility that
expression of fewer molecular alterations may also be sufficient for
transformation, we studied a number of oncogenic combinations
(summarized in Table 2). We began by testing the effects of forced
expression of hTERT and SV40 T oncoprotein. After transduction
and antibiotic selection, the resulting FTEC-SV40 T + hTERT cells
grew well in vitro and were able to avoid senescence, which was uni-
formly observed in the control FTECs after 8 to 12 weeks in culture.
However, none of four SCID mice injected with FTEC-SV40 T +
hTERT cells formed xenografts. Interestingly, transduction of these
FTEC-SV40 T + hTERT cells with a vector expressing both C-MYC
T58A and HRAS G12V did result in transformation. To test whether
expression of both HRAS G12V and C-MYC T58A oncogenes was
necessary for FTEC transformation, we investigated two FTEC lines
that were treated with an OC lacking HRAS G12V. These cells grew
readily in vitro; however, even 20 weeks after intraperitoneal injection,
none of four SCID mice formed tumors, whereas FTECs treated with
OC, which that included HRAS G12V, formed xenografts in both
animals with a latency of approximately 4 weeks.
Figure 6. Expression of OC-related proteins during FTEC-OC transformation. (A) FTEC-76 and 74 OC cells were sampled at early and late
time points after transduction and subjected to Western blot analysis along with cell lines established from their respective xenografts
(Ca). (B) Knockdown of SV40 T antigen rescues inactive p53 accumulation and leads to the induction of p21. (C) Knockdown of SV40 T
results in decreased BRCA1 expression.
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Given the ubiquitous and early involvement of p53 mutations in
serous ovarian carcinomas and their proposed histologic precursors,
we investigated the effects of combined forced telomerase activity
(through hTERT expression) and p53 dysfunction (through expres-
sion of dominant-negative p53DD). Six independent FTEC lines
were transduced and selected to force the expression of hTERT
and p53DD. All underwent growth arrest morphologic changes
consistent with senescence regardless of whether hTERT was over-
expressed first followed by p53DD or vice versa. This occurred de-
spite evidence of p53DD expression, wild-type p53 dysfunction, and
telomerase activation as demonstrated by telomere repeat amplifica-
tion protocol assay (data not shown). Thus, the combination of p53
dysfunction and telomerase activation is not sufficient for the con-
tinued proliferation of human FTEC.
Finally, after a period of sustained growth, we observed a slow
down in FTEC74-OC cells. Serial assay of the cell line using RT-
PCR revealed a decline of hTERT expression, whereas FTEC76-
OC line showed retained hTERT and proliferation (data not shown).
To test whether decreased hTERT expression was the cause of growth
slowdown, FTEC74-OC cells were treated with either an empty
retrovirus or pBabe-hTERT-neo followed by neomycin selection.
FTEC74-OC cells with forced hTERT expression regained rapid pro-
liferation, whereas the control vector–transduced cells underwent
growth arrest and senescence.
Taken together, these observations further support the findings of
our oncogenic selection model, stating that inhibition of both p53
and Rb pathways as well as activation of MYC, RAS, and telomerase
is required for the transformation of human FTEC.
Discussion
The uncertainty surrounding the tissue of origin of serous carcinoma,
the main histologic subtype of epithelial ovarian cancer, remains a
significant obstacle confronting a better understanding of the patho-
physiology of this disease. Our research provides direct evidence sup-
porting the fallopian tube origin of serous carcinoma and provides
Figure 7. Effects of oncogene knockdown in FTEC-OC cells. (A) siRNA target protein levels. (B) Growth of control and siRNA-treated
FTEC76-OC (72 hours). *P < .0001. **P < .005. Error bars represent SD. (C) Induction of p27 after siRNA treatment.
Table 2. Summary of Molecular Alterations and Associated Phenotypes.
Genetic Alteration Growth Focus Formation Senescence Xenograft (Intraperitoneal Injection)
FTEC-CC + N Y ND
FTEC-OC +++ +++ N Y
FTEC-OC with lost hTERT expression + ND Y ND
FTEC-OC with forced hTERT expression +++ +++ N Y
FTEC-OC without HRAS-G12V expression +++ +++ N N (0/4 mice)
SV40 T + hTERT + + N N (0/4 mice)
SV40 T + hTERT + HRAS G12V + C-MYC T58A ++ ++ N Y
HTERT + p53DD +/− ND N ND
N indicates not observed; ND, not done due to growth arrest/senescence; Y, observed.
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insights into the prerequisite molecular events required for the trans-
formation of human FTEC. We found that the minimal alterations
sufficient for transformation of human FTECs are interference with
p53 and Rb tumor suppressor pathways (as accomplished by SV40 T
oncoprotein), telomerase expression, and activation of Myc and Ras
pathways. These findings are consistent with observations of Kendall
et al. who showed that forced activation of MYC, RAS, and hTERT
in addition to interference with p53 and Rb tumor suppressor func-
tions were necessary and sufficient to transform human cells of epi-
thelial and mesenchymal origin [13].
While this article was in preparation, Karst et al. [25] published
their work on immortalization and subsequent transformation of
primary human fallopian tube epithelial cells. Although the method-
ologies differ, overall, the findings of these two studies are very con-
sistent, and the phenotype of the transformed FTECs in both studies
are quite similar and phenocopy that of patient-derived serous car-
cinomas commonly classified as ovarian or peritoneal cancer. Karst
et al. immortalized FTECs first by using forced expression of SV40 T,
SV40 t (small t antigen), and hTERT. They found that addition
of C-MYC or oncogenic HRAS resulted in the transformation of
xenografts in immunocompromised mice, albeit, with different po-
tencies [25]. In our study, we used growth rather than antibiotic se-
lection and found that FTECs harboring SV40 T, hTERT, HRAS
G12V, and C-MYC T58A expression are selected over time in cul-
ture and achieve transformation. The fact that our results showed
selection of both C-MYC T58A and HRAS G12V may be explained
by a greater growth advantage of cells harboring both mutations. The
clonal analysis of our transformed cells revealed that all 10 clones
from the two independent transformed FTEC lines had undergone
transduction with both HRAS G12V and C-MYC T58A vectors (as
well as SV40 T). Furthermore, we observed that FTECs treated with
an OC containing C-MYC T58A but not oncogenic HRAS were
unable to form tumors in SCID mice. These results strongly suggest
that the coexpression of these oncogenes in the same FTEC is required
for transformation. Additional evidence supporting the independent
contribution of the C-MYC and HRAS oncoproteins to FTEC trans-
formation and cell growth is gained from our knockdown experiments.
If discrete populations of transformed cells relied on either C-MYC or
HRAS expression, knocking down both oncogenes would be expected
to have an additive inhibitory effect on proliferation. However, our
experimental evidence reveals no such additive effect (Figure 7, A
and B). Finally, the inclusion of SV40 t in Karst’s model may have
compensated for the requirement of both oncogenes. For example,
SV40 t has been shown to stabilize C-MYC by inhibiting serine-
threonine protein phosphatase A (PP2A)–mediated dephosphorylation
of serine 62 thereby blocking C-MYC degradation [26]. Thus, immor-
talized FT cells that were transformed in the presence of oncogenic
HRAS alone in the model of Karst et al. may also have indirect acti-
vation of the C-MYC pathway through SV40 t expression.
Our investigation suggests that p27 protein accumulation may
be indirectly involved in FTEC transformation. Because C-MYC
opposes p27-induced arrest [23,27], increased p27 levels may act
as a selection factor for genetic alterations that result in C-MYC
activation. Furthermore, we observed that knockdown of C-MYC,
hTERT, HRAS, and SV40 T was associated with decreased cell pro-
liferation that correlated with increased p27 levels, pointing to the
potential importance of this cyclin-dependent kinase inhibitor in act-
ing as a barrier to growth and transformation. Interestingly, Norquist
et al. [9] observed a decreased p27 expression in tubal p53 foci (areas
of presumed premalignant changed in tubal epithelium) exclusively
in BRCA1 mutation carriers. This raises the intriguing possibility that
one potential contribution of BRCA1 dysfunction may be related to
the ineffective p27 response in at-risk tubal epithelium.
This investigation is the first to define a serous carcinoma–related
gene expression profile using untransformed fallopian tube epithelial
cells as the reference. It is notable that the list of differentially ex-
pressed genes in our study is distinct compared with previously pub-
lished ovarian cancer transcriptional profiling studies. This is not
surprising given that the list of differentially expressed genes is largely
dependent on the choice of the normal tissue used for comparison
[18]. We believe that FTECs represent a more relevant normal com-
parison and thus may lead to identification of ovarian cancer bio-
markers that are more closely related to the pathophysiology of this
disease. In fact, two of the most promising recently developed markers
for serous ovarian cancer, HE4 (WFDC2) and PAX8, were both ini-
tially identified in several expression profiling studies in which ovarian
cancers were compared with normal ovarian tissue, ovarian surface
cells, or a composite reference RNA consisting of mixture of various
human tissue RNAs [19,28]. However, PAX8 and HE4 are also ex-
pressed in normal fallopian tube epithelium [29,30] and, as such, may
represent markers of tissue of origin rather than ovarian carcinoma’s
malignant phenotype per se. In this regard, PAX8 has been proposed
as a specific marker for secretory FTEC [31,32]. Given that most
serous carcinomas are immunohistochemically positive for PAX8
[29,32,33], it has been proposed that secretory FTECs are the cells
of origin of serous carcinomas [34]. Our finding of uniform PAX8
positivity in the transformed FTEC74-OC and FTEC76-OC cell lines
would be consistent with such a hypothesis. However, we believe that
more rigorous testing is needed before PAX8 expression can be con-
sidered a definitive proof that secretory FTECs are the exclusive pre-
cursor cell type for serous carcinomas. PAX8 is expressed in a number
of normal and malignant gynecologic tissues including ovarian inclu-
sion cysts [32]. Furthermore, our primary FTEC cultures were com-
posed of a mixture of secretory and ciliated cells. Although it is possible
that secretory cells were preferentially transformed in our model, PAX8
positivity in transformed cells could also be a secondary marker of
dedifferentiation or transformation. Interestingly, Yamanouchi et al.
[35] have shown that, in the mouse, mesenchymal cells can determine
the secretory versus the ciliated differentiation of oviductal epithelial
cells. This raises the intriguing possibility that stromal cell interactions
may play a role in serous carcinogenesis by influencing the pheno-
type or susceptibility of FTECs. In support of this hypothesis, in-
teractions between cancer-associated and senescent fibroblasts and
ovarian cancer epithelial cells have been recently described [36,37].
Finally, the currently proposed model for serous carcinogenesis
suggests that p53 mutations or other dysfunction as evidenced by
p53 immunostaining may be the earliest precursor to serous carci-
nomas [5]. In our investigation, induced p53 dysfunction (using a
dominant-negative isoform) in combination with telomerase activa-
tion consistently led to FTEC growth arrest (presumably due to se-
nescence). This suggests that other early molecular alterations are
necessary to enable FTECs with acquired p53 dysfunction to bypass
senescence. Alternatively, our model of p53 dysfunction using a
dominant-negative isoform may not be able to completely recapitu-
late clinically observed p53 mutations, which may possess additional
gain-of-function properties [38].
In summary, we believe that in vitro models of serous carcinogen-
esis, such as the one described here, have the potential to provide a
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better understanding of early events in serous carcinogenesis that are
currently clinically undetectable.
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Table W1. Viral and Control Cocktail Components.
Laboratory Designation Addgene No. or Other ID Hyperlink
Viral cocktail
A shBRCA1-308* Homo sapiens breast cancer 1, early onset (BRCA1) … — Nucleotide result
C shBRCA1-4590† Homo sapiens breast cancer 1, early onset (BRCA1) … — Nucleotide result
S 1774 Addgene — pBABE-neo-hTERT plasmid data
T 9058 Addgene — pBABE-hygro p53 DD plasmid data
EE 9051 Addgene — pBABE puro H-Ras V12 plasmid data
GG 11129 Addgene — pbabe-cyclin D1 + CDK4R24C plasmid data
MM 18773 Addgene — MSCV Myc T58A puro plasmid data
PP 13970 Addgene — pBABE-puro SV40 LT plasmid data
AA 10668 Addgene — pBABE GFP plasmid data
Control cocktail
AA 10668 Addgene — pBABE GFP plasmid data
G pMMP-mir-gl2shRNA
Q pBabe-puro (empty vector)
*Sequence: 5′-TGCTGTTGACAGTGAGCG CCCACAAAGTGTGACCACATAT TAGTGAAGCCACAGATGTA ATATGTGGTCACACTTTGTGGA TGCCTACTGCCTCGGA.
†Sequence: 5′-TGCTGTTGACAGTGAGCG CGGAGCTGGACACCTACCTGAT TAGTGAAGCCACAGATGTA ATCAGGTAGGTGTCCAGCTCCT TGCCTACTGCCTCGGA.
Table W2. Antibody Information for Immunohistochemistry.
Target Vendor Catalog No. Dilution
p53 Dako M7001 1:10
Cytokeratin 7 Dako M7018 1:800
Cytokeratin 20 Dako M7019 1:100
WT1 Thermo Scientific PA1-38864 1:2
PAX8 ProteinTech Group 10336-1-AP 1:200
HE4 (WFDC2) Abcam ab24480 1:40
Dako, Carpinteria, CA; ProteinTech, Chicago, IL; Abcam, Cambridge, MA.
Figure W1. Hierarchical clustering of malignant signature. A total of
158 genes differentiating FTEC-OC and primary serous ovarian can-
cers from FTEC-CC and untreated normal primary FTEC were iden-
tified using F test (P< .005) and subjected to hierarchical clustering.
Expression levels of each gene are presented in Table W3. Figure W1. (continued).
Figure W1. (continued). Figure W1. (continued).
Figure W1. (continued).
Figure W2. Clonal analysis of transformed FTEC lines. Expression levels of SV40 T, HRAS G12V, and C-MYC T58A in the parental (P) and
five clonal sublines (numbered 1–5) of FTEC74-OC (A) and FTEC76-OC (B) using real-time RT-PCR. Error bars represent SD of replicates.
